Clinical Trial

Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2024 (before its estimated April 25, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate whether maintenance therapy with decitabine, venetoclax and blinatumomab could improve the 2-year progression free survival (PFS) of patients with philadelphia chromosome-negative B-cell acute lymphoblastic leukemia who had recently received an allogeneic stem cell transplant and in measurable residual disease-negative remission.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-27.
Status change: Not Yet Recruiting → Recruiting 2024-11-17
Trial Details
NCT Number NCT06393985
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions B-cell Acute Lymphoblastic Leukemia
Enrollment 30 participants
Start Date 2024-04-25
Primary Completion 2026-04-25 (estimated)
Study Completion 2027-04-25 (estimated)
Updated on ClinicalTrials.gov 2024-11-19